However, several patients suffering from chronic myeloid leukaemia and Type 2 diabetes show a marked improvement in their glucose handling and completely stop administering exogenous insulin shortly after initiating their dasatinib-based therapy for the treatment of imatinib-resistant leukaemia [39,40]. Here, INS is linked to type 2 diabetes mellitus.